The prostate cancer measures were developed by the AUA, American Medical Association's Physician Consortium for Performance Improvement (PCPI), the American Society of Clinical Oncology and the American Society for Therapeutic Radiology and Oncology.
These measures were most recently up for maintenance at the National Quality Forum (NQF) in January 2012. This means that the measures had to be retested for validity, reliability and feasibility, all factors that were evaluated when the measures were originally approved. Beginning in March 2011, the quality improvement organization Telligen was hired to perform the measure testing, which required chart and electronic medical record (EMR) abstractions from volunteer physician practice sites. The measures received full endorsement after this testing and review.
- Measure# 102 – Prostate Cancer, Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients [pdf]
- Measure# 104 – Prostate Cancer, Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients [pdf]